The future of chemotherapy in the era of personalized medicine

Maria Vittoria Dieci, Valentina Guarneri, Pierfranco Conte

Research output: Contribution to journalArticlepeer-review


Chemotherapy still represents the mainstay of therapy for many breast cancer patients. Indeed, it is the only available option for the treatment of triple-negative disease. Moreover, targeted agents, in particular anti-HER2 compounds, show the highest efficacy when combined with chemotherapy. Research efforts should therefore continue to investigate new chemotherapeutic drugs, with the attempt to increase efficacy and reduce toxicity. Similarly to targeted drugs, cytotoxic compounds should be developed in the context of personalized medicine, by adopting tools including high-throughput technologies to select sensitive patient subsets. Indeed, it seems clear by now that great advances in the general, unselected breast cancer population are no longer possible. The attention has to be moved to smaller breast cancer disease groups and this will have obvious implications in clinical trials design and conception in the next future.

Original languageEnglish
Pages (from-to)57-68
Number of pages12
JournalCurrent Breast Cancer Reports
Issue number1
Publication statusPublished - Mar 2013


  • Anti-HER2 compounds
  • Antiangiogenic agents
  • BC
  • Breast cancer
  • Chemosensitivity of BC subgroups
  • Chemotherapy
  • Cytotoxic compounds
  • MBC
  • Metastatic breast cancer
  • Personalized medicine

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'The future of chemotherapy in the era of personalized medicine'. Together they form a unique fingerprint.

Cite this